Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2013

Open Access 01-12-2013 | Letter to the Editor

The parallel lives of alpha1-antitrypsin deficiency and pulmonary alveolar proteinosis

Authors: Bruce C Trapnell, Maurizio Luisetti

Published in: Orphanet Journal of Rare Diseases | Issue 1/2013

Login to get access

Abstract

In 1963, five cases of alpha1-antitrypsin deficiency were reported in the scientific literature, as well as an attempt to treat pulmonary alveolar proteinosis by a massive washing of the lung (whole lung lavage). Now, fifty years later, it seems the ideal moment not only to commemorate these publications, but also to point out the influence both papers had in the following decades and how knowledge on these two fascinating rare respiratory disorders progressed over the years. This paper is therefore not aimed at being a comprehensive review for both disorders, but rather at comparing the evolution of alpha1-antitrypsin, a rare disorder, with that of pulmonary alveolar proteinosis, an ultra-rare disease. We wanted to emphasize how all stakeholders might contribute to the dissemination of the awareness of rare diseases, that need to be chaperoned from the ghetto of neglected disorders to the dignity of recognizable and treatable disorders.
Appendix
Available only for authorised users
Literature
1.
go back to reference Laurell C-B, Eriksson S: The electrophoretic α1- globulin pattern of serum in α1-antitrypsin deficiency. Scand J Clin Lab Invest. 1963, 15: 132-140.CrossRef Laurell C-B, Eriksson S: The electrophoretic α1- globulin pattern of serum in α1-antitrypsin deficiency. Scand J Clin Lab Invest. 1963, 15: 132-140.CrossRef
2.
go back to reference Eriksson S, Laurell C-B: A new abnormal serum globulin alpha-1 antitrypsin. Acta Chem Scand. 1963, 17: 150-153.CrossRef Eriksson S, Laurell C-B: A new abnormal serum globulin alpha-1 antitrypsin. Acta Chem Scand. 1963, 17: 150-153.CrossRef
3.
go back to reference Ramirez RJ, Schultz RB, Dutton RE: Pulmonary alveolar proteinosis. A new technique and rationale for treatment. Arch Int Med. 1963, 112: 173-185. 10.1001/archinte.1963.03860020071008.CrossRef Ramirez RJ, Schultz RB, Dutton RE: Pulmonary alveolar proteinosis. A new technique and rationale for treatment. Arch Int Med. 1963, 112: 173-185. 10.1001/archinte.1963.03860020071008.CrossRef
4.
go back to reference Rosen SH, Castelman B, Liebow AA: Pulmonary alveolar proteinosis. N Engl J Med. 1958, 258: 1123-1142. 10.1056/NEJM195806052582301.PubMedCrossRef Rosen SH, Castelman B, Liebow AA: Pulmonary alveolar proteinosis. N Engl J Med. 1958, 258: 1123-1142. 10.1056/NEJM195806052582301.PubMedCrossRef
5.
go back to reference Carrell RW: What we owe to α1- antitrypsin and to Carl-Bertil Laurell. COPD. 2004, 1: 71-84. 10.1081/COPD-120028703.PubMedCrossRef Carrell RW: What we owe to α1- antitrypsin and to Carl-Bertil Laurell. COPD. 2004, 1: 71-84. 10.1081/COPD-120028703.PubMedCrossRef
6.
go back to reference Fagerhol MK, Laurell C-B: The polymorphism of prealbumins’ and α1-antitrypsin in human sera. Clin Chim Acta. 1967, 16: 199-203. 10.1016/0009-8981(67)90181-7.PubMedCrossRef Fagerhol MK, Laurell C-B: The polymorphism of prealbumins’ and α1-antitrypsin in human sera. Clin Chim Acta. 1967, 16: 199-203. 10.1016/0009-8981(67)90181-7.PubMedCrossRef
7.
go back to reference Fagerhol MK: The Pi system. Genetic variants of α1-antitrypsin. Ser Haematol. 1968, 1: 153-161. Fagerhol MK: The Pi system. Genetic variants of α1-antitrypsin. Ser Haematol. 1968, 1: 153-161.
8.
9.
go back to reference Larsson C: Natural history and life expectancy in severe alpha1-antitrypsin deficiency, PiZ. Acta Med Scand. 1978, 204: 345-351.PubMedCrossRef Larsson C: Natural history and life expectancy in severe alpha1-antitrypsin deficiency, PiZ. Acta Med Scand. 1978, 204: 345-351.PubMedCrossRef
10.
go back to reference Sveger T: Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Eng J Med. 1976, 294: 1316-1321. 10.1056/NEJM197606102942404.CrossRef Sveger T: Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Eng J Med. 1976, 294: 1316-1321. 10.1056/NEJM197606102942404.CrossRef
11.
go back to reference Jeppsson J-O, Larsson C, Eriksson S: Characterization of α1-antitrypsin in the inclusion bodies from the liver in α1-antitrypsin deficiency. N Engl J Med. 1975, 293: 576-579. 10.1056/NEJM197509182931203.PubMedCrossRef Jeppsson J-O, Larsson C, Eriksson S: Characterization of α1-antitrypsin in the inclusion bodies from the liver in α1-antitrypsin deficiency. N Engl J Med. 1975, 293: 576-579. 10.1056/NEJM197509182931203.PubMedCrossRef
12.
go back to reference Sharp HL, Bridges RA, Krivit W, Freier EF: Cirrhosis associated with alpha-1 antitrypsin deficiency: a previously unrecognized and inherited disorder. J Lab Clin Med. 1969, 73: 934-939.PubMed Sharp HL, Bridges RA, Krivit W, Freier EF: Cirrhosis associated with alpha-1 antitrypsin deficiency: a previously unrecognized and inherited disorder. J Lab Clin Med. 1969, 73: 934-939.PubMed
13.
go back to reference Johnson D, Travis J: Structural evidence for methionine at the reactive site of human a-1- proteinase inhibitor. J Biol Chem. 1978, 253: 7142-7144.PubMed Johnson D, Travis J: Structural evidence for methionine at the reactive site of human a-1- proteinase inhibitor. J Biol Chem. 1978, 253: 7142-7144.PubMed
14.
go back to reference Johnson D, Travis J: The oxidative inactivation of human alpha-1-proteinase inhibitor. Further evidence for methionine at the reactive center. J Biol Chem. 1979, 254: 4022-4026.PubMed Johnson D, Travis J: The oxidative inactivation of human alpha-1-proteinase inhibitor. Further evidence for methionine at the reactive center. J Biol Chem. 1979, 254: 4022-4026.PubMed
16.
go back to reference Loebermann H, Tokuoka R, Deisenhofer J, Huber R: Human α1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J Mol Biol. 1984, 177: 531-556. 10.1016/0022-2836(84)90298-5.PubMedCrossRef Loebermann H, Tokuoka R, Deisenhofer J, Huber R: Human α1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J Mol Biol. 1984, 177: 531-556. 10.1016/0022-2836(84)90298-5.PubMedCrossRef
17.
go back to reference Long GL, Chandra I, Woo SLC, Davie EW, Kurachi K: Complete sequence of the cDNA for human α1-antitrypsin and the gene for the S variant. Biochemistry. 1984, 23: 4828-4837. 10.1021/bi00316a003.PubMedCrossRef Long GL, Chandra I, Woo SLC, Davie EW, Kurachi K: Complete sequence of the cDNA for human α1-antitrypsin and the gene for the S variant. Biochemistry. 1984, 23: 4828-4837. 10.1021/bi00316a003.PubMedCrossRef
18.
go back to reference Nukiwa T, Satoh K, Brantly ML, Ogushi F, Fells GA, Courtney M, Crystal RG: Identification of a second mutation in the protein coding sequence of the Z-type alpha1-antitrypsin gene. J Biol Chem. 1986, 261: 15989-15994.PubMed Nukiwa T, Satoh K, Brantly ML, Ogushi F, Fells GA, Courtney M, Crystal RG: Identification of a second mutation in the protein coding sequence of the Z-type alpha1-antitrypsin gene. J Biol Chem. 1986, 261: 15989-15994.PubMed
19.
go back to reference Buist AS, Burrows B, Eriksson S, Mittman C, Wu M: The natural history of air-flow obstruction in PiZ emphysema. Report of an NHLBI Workshop. Am Rev Respir Dis. 1983, 127 (suppl): 43-45. Buist AS, Burrows B, Eriksson S, Mittman C, Wu M: The natural history of air-flow obstruction in PiZ emphysema. Report of an NHLBI Workshop. Am Rev Respir Dis. 1983, 127 (suppl): 43-45.
20.
go back to reference Wewers MD, Casolaro MA, Sellers S, Swayze SC, McPhaul KM, Crystal RG: Replacement therapy for alpha1-antitrypsin deficiency associated with emphysema. N Engl J Med. 1987, 316: 1055-1062. 10.1056/NEJM198704233161704.PubMedCrossRef Wewers MD, Casolaro MA, Sellers S, Swayze SC, McPhaul KM, Crystal RG: Replacement therapy for alpha1-antitrypsin deficiency associated with emphysema. N Engl J Med. 1987, 316: 1055-1062. 10.1056/NEJM198704233161704.PubMedCrossRef
21.
go back to reference Seymour JF, Presneill JJ: Pulmonary alveolar proteinosis. Progress in the first 44 years. Am J Respir Crit Care Med. 2002, 166: 215-235. 10.1164/rccm.2109105.PubMedCrossRef Seymour JF, Presneill JJ: Pulmonary alveolar proteinosis. Progress in the first 44 years. Am J Respir Crit Care Med. 2002, 166: 215-235. 10.1164/rccm.2109105.PubMedCrossRef
22.
go back to reference Ramirez J, Kieffer RF, Ball WC: Bronchopulmonary lavage in man. Ann Intern Med. 1965, 63: 819-828. 10.7326/0003-4819-63-5-819.PubMedCrossRef Ramirez J, Kieffer RF, Ball WC: Bronchopulmonary lavage in man. Ann Intern Med. 1965, 63: 819-828. 10.7326/0003-4819-63-5-819.PubMedCrossRef
23.
go back to reference Happleston AG: Animal model of human disease. Pulmonary alveolar lipo-proteinosis. Animal model : silica – induced pulmonary alveolar lipo-proteinosis. Am J Pathol. 1975, 78: 171-174. Happleston AG: Animal model of human disease. Pulmonary alveolar lipo-proteinosis. Animal model : silica – induced pulmonary alveolar lipo-proteinosis. Am J Pathol. 1975, 78: 171-174.
24.
go back to reference Miller RR, Churg AM, Hutcheon M, Lom S: Pulmonary alveolar proteinosis and aluminium dust exposure. Am Rev Respir Dis. 1984, 130: 312-315.PubMed Miller RR, Churg AM, Hutcheon M, Lom S: Pulmonary alveolar proteinosis and aluminium dust exposure. Am Rev Respir Dis. 1984, 130: 312-315.PubMed
25.
go back to reference Bedrossian CW, Luna MA, Conklin RH, Miller WC: Alveolar proteinosis as a consequence of immunosuppression. A hypothesis based on clinical and pathologic observations. Hum Pathol. 1980, 11 (Suppl 5): 527-535.PubMed Bedrossian CW, Luna MA, Conklin RH, Miller WC: Alveolar proteinosis as a consequence of immunosuppression. A hypothesis based on clinical and pathologic observations. Hum Pathol. 1980, 11 (Suppl 5): 527-535.PubMed
26.
go back to reference Teja K, Cooper PH, Squires JE, Schanatterly PT: Pulmonary alveolar proteinosis in four siblings. M Engl J Med. 1981, 305: 1390-1392. 10.1056/NEJM198112033052305.CrossRef Teja K, Cooper PH, Squires JE, Schanatterly PT: Pulmonary alveolar proteinosis in four siblings. M Engl J Med. 1981, 305: 1390-1392. 10.1056/NEJM198112033052305.CrossRef
27.
go back to reference Coleman M, Dehler LP, Sibley RK, Burke BA, l’Heureux PR, Thompson TR: Pulmonary alveolar proteinosis : an uncommon cause of chronic neonatal respiratory distress. Am Rev Respir Dis. 1980, 121: 583-586.PubMedCrossRef Coleman M, Dehler LP, Sibley RK, Burke BA, l’Heureux PR, Thompson TR: Pulmonary alveolar proteinosis : an uncommon cause of chronic neonatal respiratory distress. Am Rev Respir Dis. 1980, 121: 583-586.PubMedCrossRef
28.
go back to reference Golde DW, Territo M, Finley TN, Cline MJ: Defective lung macrophages in pulmonary alveolar proteinosis. Ann Intern Med. 1976, 85: 304-309. 10.7326/0003-4819-85-3-304.PubMedCrossRef Golde DW, Territo M, Finley TN, Cline MJ: Defective lung macrophages in pulmonary alveolar proteinosis. Ann Intern Med. 1976, 85: 304-309. 10.7326/0003-4819-85-3-304.PubMedCrossRef
29.
go back to reference Claypool WD, Rogers RM, Matuschak GM: Update on the clinical diagnosis, management, and pathogenesis of pulmonary alveolar proteinosis (phospholipidosis). Chest. 1984, 85: 550-558. 10.1378/chest.85.4.550.PubMedCrossRef Claypool WD, Rogers RM, Matuschak GM: Update on the clinical diagnosis, management, and pathogenesis of pulmonary alveolar proteinosis (phospholipidosis). Chest. 1984, 85: 550-558. 10.1378/chest.85.4.550.PubMedCrossRef
30.
go back to reference Lomas DA, Evans DL, Finch JT, Carrell RW: The mechanism of Z α1-antitrypsin accumulation in the liver. Nature. 1992, 357: 605-607. 10.1038/357605a0.PubMedCrossRef Lomas DA, Evans DL, Finch JT, Carrell RW: The mechanism of Z α1-antitrypsin accumulation in the liver. Nature. 1992, 357: 605-607. 10.1038/357605a0.PubMedCrossRef
31.
go back to reference Le A, Graham KS, Sifers RN: Intracellular degradation of the transport-impaired human PiZ α1-antitrypsin variant. Biochemical mapping of the degradative event among compartments in the secretory pathway. J Biol Chem. 1990, 265: 14001-14007.PubMed Le A, Graham KS, Sifers RN: Intracellular degradation of the transport-impaired human PiZ α1-antitrypsin variant. Biochemical mapping of the degradative event among compartments in the secretory pathway. J Biol Chem. 1990, 265: 14001-14007.PubMed
32.
go back to reference Wu Y, Whitman I, Molmenti E, Moore K, Hippenmeyer P, Perlmutter DH: A lag in intracellular degradation of mutant α1-antitrypsin correlates with liver disease phenotype in homozygous PiZZ α1-antitrypsin deficiency. PNAS. 1994, 91: 9014-9018. 10.1073/pnas.91.19.9014.PubMedCentralPubMedCrossRef Wu Y, Whitman I, Molmenti E, Moore K, Hippenmeyer P, Perlmutter DH: A lag in intracellular degradation of mutant α1-antitrypsin correlates with liver disease phenotype in homozygous PiZZ α1-antitrypsin deficiency. PNAS. 1994, 91: 9014-9018. 10.1073/pnas.91.19.9014.PubMedCentralPubMedCrossRef
33.
34.
go back to reference The Alpha-1-Antitrypsin Deficiency Registry Study Group: Survival and FEV1 decline in individuals with severe deficiency of alpha1- antitrypsin. Am J Respir Crit Care Med. 1998, 158: 49-59.CrossRef The Alpha-1-Antitrypsin Deficiency Registry Study Group: Survival and FEV1 decline in individuals with severe deficiency of alpha1- antitrypsin. Am J Respir Crit Care Med. 1998, 158: 49-59.CrossRef
35.
go back to reference Dowson LJ, Guest PJ, Stockley RA: Longitudinal changes in physiological, radiological, and health status measurements in alpha (1)-antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med. 2001, 164: 1805-1809. 10.1164/ajrccm.164.10.2106036.PubMedCrossRef Dowson LJ, Guest PJ, Stockley RA: Longitudinal changes in physiological, radiological, and health status measurements in alpha (1)-antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med. 2001, 164: 1805-1809. 10.1164/ajrccm.164.10.2106036.PubMedCrossRef
36.
go back to reference Needham M, Stockley RA: Exacerbations in alpha (1)-antitrypsin deficiency. Eur Respir J. 2005, 25: 992-1000. 10.1183/09031936.05.00074704.PubMedCrossRef Needham M, Stockley RA: Exacerbations in alpha (1)-antitrypsin deficiency. Eur Respir J. 2005, 25: 992-1000. 10.1183/09031936.05.00074704.PubMedCrossRef
37.
go back to reference Dawwas MF, Davies SE, Griffths WJH, Lomas DA, Alexander GJ: Prevalence and risk factors for liver involvement in individuals with PIZZ-related lung disease. Am J Respir Crit Care Med. 2013, 187: 502-508. 10.1164/rccm.201204-0739OC.PubMedCrossRef Dawwas MF, Davies SE, Griffths WJH, Lomas DA, Alexander GJ: Prevalence and risk factors for liver involvement in individuals with PIZZ-related lung disease. Am J Respir Crit Care Med. 2013, 187: 502-508. 10.1164/rccm.201204-0739OC.PubMedCrossRef
38.
go back to reference De Serres FJ: Worldwide racial and ethnic distribution of α1-antitrypsin deficiency. Chest. 2002, 122: 1818-1829. 10.1378/chest.122.5.1818.PubMedCrossRef De Serres FJ: Worldwide racial and ethnic distribution of α1-antitrypsin deficiency. Chest. 2002, 122: 1818-1829. 10.1378/chest.122.5.1818.PubMedCrossRef
39.
go back to reference Habusriwil H, Stockley RA: Alpha1-antitrypsin replacement therapy: current status. Curr Opin Pulm Med. 2006, 12: 125-131. 10.1097/01.mcp.0000208452.57854.c6.CrossRef Habusriwil H, Stockley RA: Alpha1-antitrypsin replacement therapy: current status. Curr Opin Pulm Med. 2006, 12: 125-131. 10.1097/01.mcp.0000208452.57854.c6.CrossRef
40.
go back to reference Tonelli AR, Brantly ML: Augmentation therapy in alpha1-antitrypsin deficiency: advances and controversies. Ther Adv Respir Dis. 2010, 4: 289-312. 10.1177/1753465810373911.PubMedCrossRef Tonelli AR, Brantly ML: Augmentation therapy in alpha1-antitrypsin deficiency: advances and controversies. Ther Adv Respir Dis. 2010, 4: 289-312. 10.1177/1753465810373911.PubMedCrossRef
41.
go back to reference Chapman KR, Stockley RA, Dawkins C, Wilkes MM, Navicks RJ: Augmentation therapy for a1-antitrypsin deficiency : a meta-analysis. COPD. 2009, 6: 177-184. 10.1080/15412550902905961.PubMedCrossRef Chapman KR, Stockley RA, Dawkins C, Wilkes MM, Navicks RJ: Augmentation therapy for a1-antitrypsin deficiency : a meta-analysis. COPD. 2009, 6: 177-184. 10.1080/15412550902905961.PubMedCrossRef
42.
go back to reference Luisetti M, Travis J: Bioengineering: alpha 1-proteinase inhibitor site-specific mutagenesis. The prospect for improving the inhibitor. Chest. 1996, 110: 278S-283S. 10.1378/chest.110.6_Supplement.278S.PubMedCrossRef Luisetti M, Travis J: Bioengineering: alpha 1-proteinase inhibitor site-specific mutagenesis. The prospect for improving the inhibitor. Chest. 1996, 110: 278S-283S. 10.1378/chest.110.6_Supplement.278S.PubMedCrossRef
45.
go back to reference Wilson AA, Kwok LW, Hovav AH, Ohle SJ, Little FF, Fine A, Kotton DN: Sustained expression of α1-antitrypsin after transplantation of manipulated hematopoietic stem cells. Am J Respir Cell Mol Biol. 2008, 39: 133-141. 10.1165/rcmb.2007-0133OC.PubMedCentralPubMedCrossRef Wilson AA, Kwok LW, Hovav AH, Ohle SJ, Little FF, Fine A, Kotton DN: Sustained expression of α1-antitrypsin after transplantation of manipulated hematopoietic stem cells. Am J Respir Cell Mol Biol. 2008, 39: 133-141. 10.1165/rcmb.2007-0133OC.PubMedCentralPubMedCrossRef
46.
go back to reference Snider GL: Emphysema: the first two centuries--and beyond. A historical overview, with suggestions for future research: Part 1 & 2. Am Rev Respir Dis. 1992, 146: 1334-1344. 10.1164/ajrccm/146.5_Pt_1.1334. 1615-1622.PubMedCrossRef Snider GL: Emphysema: the first two centuries--and beyond. A historical overview, with suggestions for future research: Part 1 & 2. Am Rev Respir Dis. 1992, 146: 1334-1344. 10.1164/ajrccm/146.5_Pt_1.1334. 1615-1622.PubMedCrossRef
47.
go back to reference Stanley E, Lieschke GJ, Grail D, Metcalf D, Hodgson G, Gall JA, Maher DW, Cebon J, Sinickas V, Dunn ER: Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pethology. Proc Natl Acad Sci USA. 1994, 91: 5592-5596. 10.1073/pnas.91.12.5592.PubMedCentralPubMedCrossRef Stanley E, Lieschke GJ, Grail D, Metcalf D, Hodgson G, Gall JA, Maher DW, Cebon J, Sinickas V, Dunn ER: Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pethology. Proc Natl Acad Sci USA. 1994, 91: 5592-5596. 10.1073/pnas.91.12.5592.PubMedCentralPubMedCrossRef
48.
go back to reference Dranoff G, Crawford AD, Sedelain M, Ream B, Rashid A, Bronson RT, Dickersin GR, Bachurski CJ, Mark EL, Whitsett JA: Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science. 1994, 264: 713-716. 10.1126/science.8171324.PubMedCrossRef Dranoff G, Crawford AD, Sedelain M, Ream B, Rashid A, Bronson RT, Dickersin GR, Bachurski CJ, Mark EL, Whitsett JA: Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science. 1994, 264: 713-716. 10.1126/science.8171324.PubMedCrossRef
49.
go back to reference Huffman JA, Hull WM, Dranoff G, Mulligan RC, Whitsett JA: Pulmonary epithelial expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice. J Clin Invest. 1996, 97: 649-655. 10.1172/JCI118461.PubMedCentralPubMedCrossRef Huffman JA, Hull WM, Dranoff G, Mulligan RC, Whitsett JA: Pulmonary epithelial expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice. J Clin Invest. 1996, 97: 649-655. 10.1172/JCI118461.PubMedCentralPubMedCrossRef
50.
go back to reference Kitamura T, Tanaka N, Watanabe J, Uchida J, Kanegasaki S, Yamada Y, Nakata K: Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/ macrophage colony-stimulating factor. J Exp Med. 1999, 190: 875-880. 10.1084/jem.190.6.875.PubMedCentralPubMedCrossRef Kitamura T, Tanaka N, Watanabe J, Uchida J, Kanegasaki S, Yamada Y, Nakata K: Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/ macrophage colony-stimulating factor. J Exp Med. 1999, 190: 875-880. 10.1084/jem.190.6.875.PubMedCentralPubMedCrossRef
51.
go back to reference Shibata Y, Berclaz P-Y, Chroneos ZC, Whitsett JA, Trapnell BC: GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity. 2001, 15: 557-567. 10.1016/S1074-7613(01)00218-7.PubMedCrossRef Shibata Y, Berclaz P-Y, Chroneos ZC, Whitsett JA, Trapnell BC: GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity. 2001, 15: 557-567. 10.1016/S1074-7613(01)00218-7.PubMedCrossRef
52.
go back to reference Sakagami T, Uchida K, Suzuki T, Carey BC, Wood RE, Wert SE, Whitsett JA, Trapnell BC, Luisetti M: Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis. N Engl J Med. 2009, 361: 2679-2681. 10.1056/NEJMc0904077.PubMedCentralPubMedCrossRef Sakagami T, Uchida K, Suzuki T, Carey BC, Wood RE, Wert SE, Whitsett JA, Trapnell BC, Luisetti M: Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis. N Engl J Med. 2009, 361: 2679-2681. 10.1056/NEJMc0904077.PubMedCentralPubMedCrossRef
53.
go back to reference Suzuki T, Sakagami T, Young LR, Carey BC, Wood RE, Luisetti M, Wert SE, Rubin BK, Kevill K, Chalk C, Whitsett JA, Stevens C, Nogee LM, Campo I, Trapnell BC: Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy. Am J Respir Crit Care Med. 2010, 182: 1292-1304. 10.1164/rccm.201002-0271OC.PubMedCentralPubMedCrossRef Suzuki T, Sakagami T, Young LR, Carey BC, Wood RE, Luisetti M, Wert SE, Rubin BK, Kevill K, Chalk C, Whitsett JA, Stevens C, Nogee LM, Campo I, Trapnell BC: Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy. Am J Respir Crit Care Med. 2010, 182: 1292-1304. 10.1164/rccm.201002-0271OC.PubMedCentralPubMedCrossRef
54.
go back to reference Beccaria M, Luisetti M, Rodi G, Corsico A, Zoia MC, Colato S, Pochetti P, Braschi A, Pozzi E, Cerveri I: Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis. Eur Respir J. 2004, 23: 526-531. 10.1183/09031936.04.00102704.PubMedCrossRef Beccaria M, Luisetti M, Rodi G, Corsico A, Zoia MC, Colato S, Pochetti P, Braschi A, Pozzi E, Cerveri I: Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis. Eur Respir J. 2004, 23: 526-531. 10.1183/09031936.04.00102704.PubMedCrossRef
55.
go back to reference Luisetti M, Kadija Z, Mariani F, Rodi G, Campo I, Trapnell BC: Therapy options in pulmonary alveolar proteinosis. Ther Adv Respir Dis. 2010, 4: 239-248. 10.1177/1753465810378023.PubMedCrossRef Luisetti M, Kadija Z, Mariani F, Rodi G, Campo I, Trapnell BC: Therapy options in pulmonary alveolar proteinosis. Ther Adv Respir Dis. 2010, 4: 239-248. 10.1177/1753465810378023.PubMedCrossRef
56.
go back to reference Seymour JF, Presneill JJ, Schoch OD, Downie GH, Moore PE, Doyle IR, Vincent JM, Nakata K, Kitamura T, Langton D, Pain MC, Dunn AR: Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Care Med. 2001, 163: 524-531. 10.1164/ajrccm.163.2.2003146.PubMedCrossRef Seymour JF, Presneill JJ, Schoch OD, Downie GH, Moore PE, Doyle IR, Vincent JM, Nakata K, Kitamura T, Langton D, Pain MC, Dunn AR: Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Care Med. 2001, 163: 524-531. 10.1164/ajrccm.163.2.2003146.PubMedCrossRef
57.
go back to reference Tazawa R, Trapnell BC, Inoue Y, Arai T, Takada T, Nasuhara Y, Hizawa N, Kasahara Y, Tatsumi K, Hojo M, Ishii H, Yokoba M, Tanaka N, Yamaguchi E, Tsuchiashi N, Morimoto K, Akira M, Terada M, Otsuka J, Ebina M, Kaneko C, Nukiwa T, Krischer JP, Akazawa K, Nakata K: Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2010, 181: 1345-1354. 10.1164/rccm.200906-0978OC.PubMedCentralPubMedCrossRef Tazawa R, Trapnell BC, Inoue Y, Arai T, Takada T, Nasuhara Y, Hizawa N, Kasahara Y, Tatsumi K, Hojo M, Ishii H, Yokoba M, Tanaka N, Yamaguchi E, Tsuchiashi N, Morimoto K, Akira M, Terada M, Otsuka J, Ebina M, Kaneko C, Nukiwa T, Krischer JP, Akazawa K, Nakata K: Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2010, 181: 1345-1354. 10.1164/rccm.200906-0978OC.PubMedCentralPubMedCrossRef
58.
go back to reference Kavuru MS, Malur A, Marshall I, Barna BP, Meziane M, Huizar I, Dalrymple H, Karnekar R, Thomassen MJ: An open-label trial of rituximab therapy in pulmonary alveolar proteinosis. Eur Respir J. 2011, 38: 1361-1367. 10.1183/09031936.00197710.PubMedCrossRef Kavuru MS, Malur A, Marshall I, Barna BP, Meziane M, Huizar I, Dalrymple H, Karnekar R, Thomassen MJ: An open-label trial of rituximab therapy in pulmonary alveolar proteinosis. Eur Respir J. 2011, 38: 1361-1367. 10.1183/09031936.00197710.PubMedCrossRef
60.
go back to reference Inoue Y, Trapnell BC, Tazawa R, Arai T, Takada T, Hizawa N, Kasahara W, Tatsumi K, Hojo M, Ichiwata T, Tanaka N, Yamaguchi E, Eda R, Oishi K, Tsushihashi O, Kaneko C, Nukiwa T, Sakatani N, Krischer JP, Nakata K, for the Japanese Center for the Lung Lung Disease Consortium: Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med. 2008, 177: 752-762. 10.1164/rccm.200708-1271OC.PubMedCentralPubMedCrossRef Inoue Y, Trapnell BC, Tazawa R, Arai T, Takada T, Hizawa N, Kasahara W, Tatsumi K, Hojo M, Ichiwata T, Tanaka N, Yamaguchi E, Eda R, Oishi K, Tsushihashi O, Kaneko C, Nukiwa T, Sakatani N, Krischer JP, Nakata K, for the Japanese Center for the Lung Lung Disease Consortium: Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med. 2008, 177: 752-762. 10.1164/rccm.200708-1271OC.PubMedCentralPubMedCrossRef
61.
go back to reference Campo I, Mariani F, Rodi G, Paracchini E, Tsana E, Piloni D, Nobili I, Kadija Z, Corsico A, Cerveri I, Chalk C, Trapnell BC, Braschi A, Tinelli C, Luisetti M: Assessment and management of pulmonary alveolar proteinosis in a reference center. Orphanet J Rare Dis. 2013, 8: 40. 10.1186/1750-1172-8-40.PubMedCentralPubMedCrossRef Campo I, Mariani F, Rodi G, Paracchini E, Tsana E, Piloni D, Nobili I, Kadija Z, Corsico A, Cerveri I, Chalk C, Trapnell BC, Braschi A, Tinelli C, Luisetti M: Assessment and management of pulmonary alveolar proteinosis in a reference center. Orphanet J Rare Dis. 2013, 8: 40. 10.1186/1750-1172-8-40.PubMedCentralPubMedCrossRef
62.
go back to reference Stockley RA, Luisetti M, Miravitlles M, Piituilanen E, Fernandez P, on behalf of the Alpha One International Registry (AIR): Ongoing reserach in Europe: Alpha One International Registry (AIR) objective and development. Eur Respir J. 2007, 29: 582-586. 10.1183/09031936.00053606.PubMedCrossRef Stockley RA, Luisetti M, Miravitlles M, Piituilanen E, Fernandez P, on behalf of the Alpha One International Registry (AIR): Ongoing reserach in Europe: Alpha One International Registry (AIR) objective and development. Eur Respir J. 2007, 29: 582-586. 10.1183/09031936.00053606.PubMedCrossRef
63.
go back to reference Blanco I, de Serres FJ, Cárcaba V, Lara B, Fernández-Bustillo E: Alpha-1 Antitrypsin Deficiency PI*Z and PI*S Gene Frequency Distribution Using on Maps of the World by an Inverse Distance Weighting (IDW) Multivariate Interpolation Method. Hepat Mon. 2012, 12: e7434.PubMedCentralPubMedCrossRef Blanco I, de Serres FJ, Cárcaba V, Lara B, Fernández-Bustillo E: Alpha-1 Antitrypsin Deficiency PI*Z and PI*S Gene Frequency Distribution Using on Maps of the World by an Inverse Distance Weighting (IDW) Multivariate Interpolation Method. Hepat Mon. 2012, 12: e7434.PubMedCentralPubMedCrossRef
64.
go back to reference Miravitlles M, Herr C, Ferrarotti I, Jardi R, Rodriguez-Frias F, Luisetti M, Bals R: Laboratory testing of individuals with severe α1-antitrypsin deficiency in three European Centres. Eur Respir J. 2010, 35: 960-968. 10.1183/09031936.00069709.PubMedCrossRef Miravitlles M, Herr C, Ferrarotti I, Jardi R, Rodriguez-Frias F, Luisetti M, Bals R: Laboratory testing of individuals with severe α1-antitrypsin deficiency in three European Centres. Eur Respir J. 2010, 35: 960-968. 10.1183/09031936.00069709.PubMedCrossRef
65.
go back to reference Walsh JW, Snider GL, Stoller JK: A review of the Alpha-1 Foundation : its formation, impact, and critical success factors. Respir Care. 2006, 51: 526-531.PubMed Walsh JW, Snider GL, Stoller JK: A review of the Alpha-1 Foundation : its formation, impact, and critical success factors. Respir Care. 2006, 51: 526-531.PubMed
67.
go back to reference Luisetti M: Call for an International survey on therapeutic lavage for pulmonary alveolar proteinosis. Eur Respir J. 2012, 39: 1049. 10.1183/09031936.00226311.PubMedCrossRef Luisetti M: Call for an International survey on therapeutic lavage for pulmonary alveolar proteinosis. Eur Respir J. 2012, 39: 1049. 10.1183/09031936.00226311.PubMedCrossRef
68.
go back to reference Dirksen A, Dijkam JH, Madsen F, Stoel B, Hutchison DC, Ulrik CS, Skovgaard LT, Kok-Jensen A, Rudolphus A, Seersholm N, Vrooman HA, Reiber JH, Hansen NC, Hecksher T, Viskum K, Stolk J: A randomized clinical trial of α1-antitrypsin augmentation therapy. Am J Respir Crit Care Med. 1999, 160: 1468-1472. 10.1164/ajrccm.160.5.9901055.PubMedCrossRef Dirksen A, Dijkam JH, Madsen F, Stoel B, Hutchison DC, Ulrik CS, Skovgaard LT, Kok-Jensen A, Rudolphus A, Seersholm N, Vrooman HA, Reiber JH, Hansen NC, Hecksher T, Viskum K, Stolk J: A randomized clinical trial of α1-antitrypsin augmentation therapy. Am J Respir Crit Care Med. 1999, 160: 1468-1472. 10.1164/ajrccm.160.5.9901055.PubMedCrossRef
69.
go back to reference Parr DG, Stoel BC, Stolk J, Stockely RA: Pattern of emphysema distribution in α1-antitrypsin deficiency influences lung function impairment. Am J Respir Crit Care Med. 2004, 170: 1172-1178. 10.1164/rccm.200406-761OC.PubMedCrossRef Parr DG, Stoel BC, Stolk J, Stockely RA: Pattern of emphysema distribution in α1-antitrypsin deficiency influences lung function impairment. Am J Respir Crit Care Med. 2004, 170: 1172-1178. 10.1164/rccm.200406-761OC.PubMedCrossRef
70.
go back to reference Stockley RA, Parr DG, Piitulainen E, Stolk J, Stoel BC, Dirksen A: Therapeutic efficacy of alpha1-antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of two randomized clinical trials using computed tomography densitometry. Respir Res. 2010, 11: 36. 10.1186/1465-9921-11-36.CrossRef Stockley RA, Parr DG, Piitulainen E, Stolk J, Stoel BC, Dirksen A: Therapeutic efficacy of alpha1-antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of two randomized clinical trials using computed tomography densitometry. Respir Res. 2010, 11: 36. 10.1186/1465-9921-11-36.CrossRef
71.
go back to reference Coxson HO, Diksen A, Edwards LD, Yates JC, Agusti A, Bakke P, Calverly PMA, Celli B, Crim C, Duvoix A, Nasute Fauerback P, Lomas DA, MacNee W, Mayer RJ, Miller BE, Muller NL, Rennard SI, Silverman EK, Tal-Singer R, Wouters EFM, Vestbo J, for ECLIPSE Investigators: The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis form the ECLIPSE study. Lancet Respir Med. 2013, 1: 129-136. 10.1016/S2213-2600(13)70006-7.PubMedCrossRef Coxson HO, Diksen A, Edwards LD, Yates JC, Agusti A, Bakke P, Calverly PMA, Celli B, Crim C, Duvoix A, Nasute Fauerback P, Lomas DA, MacNee W, Mayer RJ, Miller BE, Muller NL, Rennard SI, Silverman EK, Tal-Singer R, Wouters EFM, Vestbo J, for ECLIPSE Investigators: The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis form the ECLIPSE study. Lancet Respir Med. 2013, 1: 129-136. 10.1016/S2213-2600(13)70006-7.PubMedCrossRef
72.
go back to reference Carrell RW, Lomas DA: Alpha1antitrypsin deficiency. A model for conformational diseases. N Engl J Med. 2002, 346: 45-53. 10.1056/NEJMra010772.PubMedCrossRef Carrell RW, Lomas DA: Alpha1antitrypsin deficiency. A model for conformational diseases. N Engl J Med. 2002, 346: 45-53. 10.1056/NEJMra010772.PubMedCrossRef
73.
go back to reference Stoller JK, Aboussouan LS: α1-antitrypsin deficiency. Lancet. 2005, 365: 2225-2236. 10.1016/S0140-6736(05)66781-5.PubMedCrossRef Stoller JK, Aboussouan LS: α1-antitrypsin deficiency. Lancet. 2005, 365: 2225-2236. 10.1016/S0140-6736(05)66781-5.PubMedCrossRef
74.
go back to reference Silverman EJ, Sandhaus RA: Alpha1 antitrypsin deficiency. N Engl J Med. 2009, 360: 2749-2757. 10.1056/NEJMcp0900449.PubMedCrossRef Silverman EJ, Sandhaus RA: Alpha1 antitrypsin deficiency. N Engl J Med. 2009, 360: 2749-2757. 10.1056/NEJMcp0900449.PubMedCrossRef
75.
go back to reference Trapnell BC, Whitsett JA, Nakata K: Pulmonary alveolar proteinosis. N Engl J Med. 2003, 349: 2527-2539. 10.1056/NEJMra023226.PubMedCrossRef Trapnell BC, Whitsett JA, Nakata K: Pulmonary alveolar proteinosis. N Engl J Med. 2003, 349: 2527-2539. 10.1056/NEJMra023226.PubMedCrossRef
Metadata
Title
The parallel lives of alpha1-antitrypsin deficiency and pulmonary alveolar proteinosis
Authors
Bruce C Trapnell
Maurizio Luisetti
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2013
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/1750-1172-8-153

Other articles of this Issue 1/2013

Orphanet Journal of Rare Diseases 1/2013 Go to the issue